Search
Tefidsogene civaparvovec
go.drugbank.com/drugs/DB16789InvestigationalDeveloped by Sangamo Therapeutics, tefidsogene civaparvovec is being investigated in mucopolysaccharidosis type II.[A258789, L45949] … It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes
Viralym-C
go.drugbank.com/drugs/DB17975InvestigationalIt was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.
Pentanal
go.drugbank.com/drugs/DB01919ExperimentalPentanal is an aldehyde that is liquid at room temperature. It is occasionally a minor ingredient in some cosmetic products like perfumes.[L53886,L53891]
Oxatomide
go.drugbank.com/drugs/DB12877ApprovedOxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
Parthenolide
go.drugbank.com/drugs/DB13063ApprovedInvestigationalParthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Neopterin
go.drugbank.com/drugs/DB15050InvestigationalNeopterin is under investigation in clinical trial NCT02974192 (Neopterin Effects on Ischemic Stroke).
Elbimilast
go.drugbank.com/drugs/DB20663InvestigationalElbimilast is under investigation in clinical trial NCT00977886 (Safety and Pharmacokinetics of ELB353 in Healthy Men). Elbimilast has a monoisotopic molecular weight of 442.04 Da. … Elbimilast is a small molecule drug. The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor.
GC5107
go.drugbank.com/drugs/DB17604InvestigationalGC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)